Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to an MDM2 targeting moiety through a linker and reported to be useful for the treatment of cancer.

Hangzhou Tianji Jishi Biotechnology Co. Ltd. has divulged naphthylamine compounds reported to be useful as mitophagy inducers.

Therabest Co. Ltd. has identified glutathione (GSH) or hydrogen peroxide (H2O2)-activated prodrugs comprising obeticholic acid dimers conjugated via linkers and their nanogels coated with fucoidan reported to be useful for the treatment of liver diseases.

Xenon Pharmaceuticals Inc. has synthesized pyridinyl derivatives acting as sodium channel protein type 1 subunit α (SCN1A; Nav1.1) activators reported to be useful for the treatment of epilepsy.

China’s National Institute of Pharmaceutical R&D...

East China University of Science & Technology has described pteridinone derivatives acting as epidermal growth factor receptor (EGFR; HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.

University of Durham has divulged heteroaryl derived compounds reported to be useful for the treatment of leishmaniasis and allergy.

Zeno Management Inc. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.

China Pharmaceutical University has synthesized receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of ischemic stroke, among others.

Janssen Pharmaceutica NV has disclosed IL-17A/IL-17 receptor A (IL-17RA) interaction modulators reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), multiple sclerosis, asthma and more.